Don’t Miss Out on the Latest Updates.
Subscribe to Our Newsletter Today!
British researchers have claimed Wednesday that taking Modafinil, a drug typically used to treat sleep disorders along with anti-depressants, reduces the severity of depression more effectively than taking anti-depressants alone.
The new study by the University of Cambridge in collaboration with the University of East London and the King's College London, was published in the online Journal of Clinical Psychiatry.
Researchers claimed that the new findings would help many individuals for whom anti-depressants give little or no relief.
According to them, a third of depressed patients receive little or no benefit from taking anti-depressants, even after they used these along with psychological counselling and of those who respond to treatment, symptoms such as fatigue and trouble in sleeping pose risk factors for relapse.
The study has claimed that those supplementing anti-depressants with Modafinil would stood to benefit.
Cynthia Fu, a professor in the University of East London, who undertook the research at the King's College London described it as good news for individuals struggling to fight depression.
'Depression affects all aspects of life, leading to occupational and social disability at varying levels. It is particularly important that people receive effective treatment as the residual symptoms e.g., fatigue, lack of concentration etc. can persist and have a negative impact on their lives,' Fu said. (Read: 'Depression is as common as the common cold nowadays')
The scientists examined the use of Modafinil as an add-on treatment for depression.
The survey involved a total of 568 patients with unipolar depression, and a total of 342 patients with bipolar depression.
It revealed that Modafinil improved the severity of depression, as well as remission rates.
Modafinil also showed good effects on fatigue and sleepiness with added benefit of the comparable side effects of placebo.
A placebo is a medically ineffectual treatment for a disease or other medical condition intended to deceive the recipient.
Depression is a major global health problem across the world. (Read: Bored? You could actually be suffering from depression!)
According to the World Health Organisation, it is estimated to be the second leading cause of disability worldwide by 2020.
What is depression?
As an illness, depression is as debilitating as a heart disease or HIV/AIDS. Those who suffer from the condition often describe the feeling as having a black cloud over their heads, which prevents them from enjoying anything or even functioning normally. One out of 20 people in the world suffer from depression but sadly many of them are forced to live in denial about the disease.
So how is depression different from sadness?
Sadness is part of the life without which happiness would have no meaning. To feel sad during major life crises like the death of a loved one, losing a job or the ending of a relationship is normal. Depression on the other hand is a condition where there is prolonged sadness and an individual's mood isn't tied to life events. While healthy individuals have moods related to life events, people suffering from depression suffer from disproportionate amount of sadness and guilt. It is a serious medical condition in which the symptoms make it difficult for the person to function in society, often leads to poor physical health and severe emotional pain.
How common is depression?
One out of every 20 people you know probably suffers from depression. The numbers are hard to pin down for a mental illness like depression because the symptoms are seen as a continuation of everyday-life behaviour. However, considering that 1.8 lakh Indians commit suicide every year and there are 20 times more attempts, which mean at least 36 lakh people in India are surely suffering from major depressive disorder. Read on
Source: IANS
For more articles, visit our Diseases and Conditions Section and for videos check out our YouTube Channel. Don't miss out on the latest updates. Follow us on Facebook, Twitter and Google Plus.